ArticleInternational journal of retina and vitreous2026
Real-world performance of faricimab for neovascular age-related macular degeneration and diabetic macular edema: experience from the BrazilRetNet multicenter study. Report 1.
Article in International journal of retina and vitreous, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Four-Year Outcomes of Faricimab in Diabetic Macular Edema in the RHONE-X Extension Trial: A Podcast.Ophthalmology and therapy · 2026Review
- From Trials to Treatment: Current Evidence Supporting Faricimab Use in nAMD and DME.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo investigate real-world use of faricimab for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).
methodsIn this first analysis of the BrazilRetNet study group, we performed a multicenter, retrospective chart review of patients who completed the first three intravitreal injections of faricimab until October 2025; patients were followed in 15 retinal centers across Brazil. Collected data included clinical and demographic information, treatment strategy and history; main outcome measures were best-corrected visual acuity (BCVA) converted in ETDRS, macular central subfield thickness (CST) measured on optical coherence tomography (OCT), and adverse events. For comparison among baseline and follow-up variables, Wilcoxon test was employed; p values ≦ 0.05 were considered statistically significant.
resultsA total of 220 patients’ eyes were included. 145 eyes of 127 nAMD patients (56% women, average 78.6 ± 9.4 years-old, 94.5% caucasian) and 75 eyes of 54 DME patients (63% men, average 66.6 ± 10.9 years old, 83.3% caucasian). Prior intravitreal treatment was reported in 123 eyes (84.8%) with nAMD and 60 eyes (80%) with DME, with a mean of 16.8 and 11.7 previous injections, respectively. Baseline mean BCVA was 57.09 (nAMD) and 63.54 (DME). After three injections, mean BCVA improved to 61.06 for nAMD (p < 0.001; average gain of 3.97 letters) and 70.27 for DME (p < 0.001; average gain of 6.73 ETDRS letters). Baseline mean CST was 320.4 μm (nAMD) and 380.4 μm (DME), decreased to 264.3 μm (nAMD; p < 0.001; − 56.1 μm) and 312.7 μm (DME; p < 0.001; − 67.7 μm). Differences on BCVA and CST remained statistically significant when subgroups of naive or previously treated eyes were analyzed. All reported adverse events occurred in nAMD patients and included submacular hemorrhage (2 eyes), RPE tear (1 eye) and increased intraocular pressure (1 eye). No intraocular inflammation was reported.
conclusionsOverall, nAMD and DME patients treated with faricimab in this Brazilian cohort, presented BCVA improvement and a decreased CST after three injections. A low incidence of adverse events was reported, mostly associated to the natural history of the disease. Future analyses will provide further information on real-world farcimab treatment for nAMD and DME in Brazil.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.